F-1: PainReform Ltd. Announces Proposed Public Offering of Ordinary Shares, Warrants

PainReform Ltd. is planning a best-efforts public offering involving ordinary shares, pre-funded warrants, common warrants, and placement agent warrants.

Summary

• PainReform Ltd. has filed a Form F-1 registration statement for a proposed public offering.
• The offering includes ordinary shares, pre-funded warrants, common warrants, and placement agent warrants.
• The ordinary shares are listed on the Nasdaq under the symbol PRFX, with a last reported sale price of $1.90 on February 29, 2024.
• The offering is on a best-efforts basis, with no minimum offering amount required.
• The company intends to use the net proceeds from this offering to advance clinical studies and for general corporate purposes.
• The placement agent will receive a cash fee equal to 7.0% of the gross proceeds raised in this offering.
• The company has granted the Placement Agent a right of first refusal for a period of 12 months following the closing of this offering to act as exclusive financial advisor, sole book-running manager, sole underwriter, sole placement agent or sole agent for each and every future debt financing or refinancing and public or private equity or debt offering or acquisition or disposition by us or any of our successors or subsidiaries.

Sentiment

Score: 6

Explanation: The document is neutral in tone, primarily outlining the details of a proposed public offering. While it highlights the intended use of proceeds for clinical studies, it also acknowledges the risks associated with the offering and the company's operations.

Positives

• The company intends to use the net proceeds from this offering to advance clinical studies and for general corporate purposes.

Negatives

• The offering is on a best-efforts basis, with no minimum offering amount required, which may result in the company receiving significantly less in net proceeds.
• There is no established trading market for the pre-funded warrants or the common warrants, and the company does not expect an active trading market to develop.
• Investing in the company's securities involves a high degree of risk, as detailed in the Risk Factors section of the prospectus.

Risks

• The best efforts structure of this offering may have an adverse effect on our business plan.
• The company may have insufficient capital to implement its business plan, potentially resulting in greater operating losses.
• The company's management team will have immediate and broad discretion over the use of the net proceeds from this offering and may not use them effectively.
• Conditions in the Middle East and in Israel may harm the company's operations.
• The company may sell in this offering up to ordinary shares, or approximately % of our outstanding ordinary shares, prior to this offering, as of , 2024, which could cause the price of our ordinary shares to decline.

Future Outlook

The company currently intends to use the net proceeds of this offering to advance its clinical studies and for general corporate purposes. Pending such uses, the company intends to invest the net proceeds in bank deposits.

Industry Context

PainReform is a clinical-stage specialty pharmaceutical company focused on the reformulation of established therapeutics, specifically targeting the post-operative pain relief market with its lead product candidate, PRF-110.

Comparison to Industry Standards

• The document does not contain sufficient information to make a detailed comparison to industry standards.
• Without specific financial data or clinical trial results, it is difficult to benchmark PainReform against competitors like Pacira BioSciences (maker of EXPAREL) or Heron Therapeutics (maker of ZYNRELEF).
• A thorough comparison would require analyzing factors such as market share, R&D spending, clinical trial success rates, and regulatory approval timelines.

Stakeholder Impact

• The offering will dilute the ownership interest of existing shareholders.
• The company intends to use the net proceeds from this offering to advance clinical studies, which could benefit patients in the future.
• The company's operations may be affected by conditions in the Middle East and in Israel, which could impact employees and investors.

Next Steps

• The company will determine the final public offering price for the securities in this offering at the time of pricing.
• The company will deliver the securities being offered pursuant to this prospectus on or about , 2024, subject to satisfaction of certain customary closing conditions.

Key Dates

Keywords

public offering, ordinary shares, pre-funded warrants, common warrants, placement agent, PRF-110, PainReform